Although angiotensin converting enzyme (ACE) inhibitors and beta blockers continue to dominate the congestive heart failure (CHF) medication markets, a wide array of emerging treatments could significantly expand the therapeutic arsenal against CHF. More than 19 new products are in the research and development pipeline and participants are expected to submit additional applications to the FDA in the near future.

New therapeutic classes, including angiotensin II receptor blockers and tumor necrosis factor inhibitors, will join a range of products, from natiuretic peptides to gene therapies, in the quest to effectively prevent, treat, and manage CHF.

This Frost & Sullivan study analyzes the markets for ACE inhibitors, beta blockers, and emerging therapeutics. With its in-depth evaluations of market drivers, restraints, and expert forecasts, this report is an essential guide to the future of a fast-growing field.

End User Preference Intensifies Competition

"Generic invasion of the CHF market is a substantial threat to the market's overall earnings potential," writes the study's author. Because generic products offer lower prices, manufacturers of branded drugs will be drawn into pricing wars to compete, and many could see revenues decline." The reduction of potential earnings could continue if cost-conscious managed care organizations and physicians rapidly adopt generics at the expense of branded versions. This report identifies challenges that all industry participants will face, helping your company anticipate and overcome any hurdles that may lay ahead.

Patient and Healthcare Provider Educational Programs Crucial for Industry Winners

"Improving education and bolstering knowledge of patients, physicians, and other healthcare professionals in the CHF medication industry is necessary for optimal treatment and market penetration," says the author. Currently, the level of education in the CHF arena is inadequate for proper therapy administration, maintenance, and product use.

By highlighting previously unexplored areas and offering strategic recommendations about new products and therapies, this research helps to optimize market penetration, increase product awareness, and maximize gains.

Related Reports:
Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
Pharmaceuticals Industry Report
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes
Prescription Drug Wholesaling in the US - Industry Risk Rating Report
Antidepressants Market Forecast
Snapshots Australia Pharmaceuticals 2009
Snapshots Bulgaria Pharmaceuticals 2009
Snapshots France Pharmaceuticals 2009
The US Government's Financial Support to Push Comparative Effectiveness Research
Anticonvulsants Market Forecast